Dains Corporate Finance advises on the sale of Creative Medical Research Limited.

Dains Corporate Finance provides due diligence services to Kerv in support of the acquisition of cloudThing.


Roy Farmer

Deal Summary

The Dains Corporate Finance team has recently advised the shareholders of Evella Holdings Limited, which includes the businesses of Creative Medical Research (CMR), MediVoice Recruit, and Healthcare Fieldwork, on the sale to Legacy Health Capital.

CMR and MediVoice provide comprehensive healthcare product development and commercial market research, and analysis, as well as participant recruitment for medical product fieldwork research across the US, the UK, and globally.  Under the guidance of the Managing Partner of Legacy Health Capital and CEO of Velox, Suman Datta, the acquisition of Evella Group represents the first acquisition of Velox’s journey.

Our role

Dains provided business sales services to Evella, managing the overall sales process from start to finish. Services included forming an underlying review of the business in advance of a sale, preparation of a sales document, advice on valuation and transaction structure, introduction to lawyers, and the overall project management of the sale process.

What our client said

George Ashford, Managing Director of CMR, said: “Having now worked with Dains on two transactions (an MBO and a business sale), I have no hesitation in recommending them to anyone else going through the same process. Their advice and support along the journey was invaluable in terms of providing understanding around processes and tax planning whilst also helping to maximise the consideration achieved.”

What we said

Roy Farmer, Corporate Finance Partner at Dains, said: “Having worked with George on the initial MBO in 2014 and the subsequent sale I am delighted with the result that we have achieved for George. This transaction will allow George to further grow his business under the ownership of Velox, as part of the new group’s wider aim to build out the key services required across the development and commercialisation path of a medical device, diagnostic, and digital health product and create a single-source solution.”